SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001714899-24-000075
Filing Date
2024-02-27
Accepted
2024-02-27 08:03:38
Documents
19
Period of Report
2024-02-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20240227.htm   iXBRL 8-K 48751
2 EX-4.1 a41denali-2024pipexformofp.htm EX-4.1 119381
3 EX-10.1 a101pipespa.htm EX-10.1 254998
4 EX-10.2 exhibit102nominatingagreem.htm EX-10.2 170014
5 EX-99.1 pipepressrelease99122724.htm EX-99.1 13932
9 denali_txlogox02.jpg GRAPHIC 604226
  Complete submission text file 0001714899-24-000075.txt   1675663

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20240227.xsd EX-101.SCH 1934
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20240227_lab.xml EX-101.LAB 23834
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20240227_pre.xml EX-101.PRE 12530
20 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20240227_htm.xml XML 2730
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 24682051
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)